|
ハギワラ シヨウタロウ
萩原 將太郎 所属 医学部 医学科（東京女子医科大学病院） 職種 非常勤講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. |
| 掲載誌名 | 正式名：International journal of hematology 略 称：Int J Hematol ISSNコード：18653774/09255710 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.in press |
| 著者・共著者 | Minakata Daisuke†, Ishida Tadao, Ando Kiyoshi, Suzuki Rikio, Tanaka Junji, Hagiwara Shotaro, Ananthakrishnan Revathi, Kuwayama Shigeki, Nishio Mitsufumi, Kanda Yoshinobu, Suzuki Kenshi |
| 発行年月 | 2023/01 |
| 概要 | BACKGROUND:In the phase 2 KarMMa trial, patients with relapsed/refractory multiple myeloma (RRMM) achieved deep and durable responses with idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell therapy. Here we report a sub-analysis of the Japanese cohort of KarMMa.METHODS:Adult patients with RRMM who had received ≥ 3 prior treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and had disease refractory to last treatment received ide-cel at a target dose of 450 × 106 CAR positive T cells.RESULTS:Nine patients were treated with ide-cel. The overall response rate was 89% (median follow-up, 12.9 months). The best overall response was stringent complete response in 5 patients (56%), very good partial response in 3 (33%), and stable disease in 1. Median duration of response was not reached. All patients experienced grade ≤ 2 cytokine release syndrome and one patient experienced grade 2 neurotoxicity, but all resolved. Two patients died, one each from plasma cell myeloma and general health deterioration.CONCLUSION:Ide-cel yielded deep, durable responses with a tolerable and predictable safety profile in Japanese patients with RRMM. These results are similar to those of the non-Japanese population in KarMMa. |
| DOI | 10.1007/s12185-023-03538-6 |
| PMID | 36690910 |